<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619359</url>
  </required_header>
  <id_info>
    <org_study_id>0517-017</org_study_id>
    <secondary_id>MK0517-017</secondary_id>
    <secondary_id>2007_594</secondary_id>
    <nct_id>NCT00619359</nct_id>
  </id_info>
  <brief_title>Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)</brief_title>
  <acronym>EASE</acronym>
  <official_title>A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Cisplatin Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to
      prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin
      chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).</measure>
    <time_frame>Overall (in the 120 hours following initiation of cisplatin chemotherapy).</time_frame>
    <description>The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 120 hours following initiation of cisplatin chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).</measure>
    <time_frame>Delayed phase (25 to 120 hours following initiation of cisplatin).</time_frame>
    <description>The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 25 to 120 hours following initiation of cisplatin chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No Vomiting Overall (in the 120 Hours Following Initiation of Cisplatin)</measure>
    <time_frame>Overall (the 120 hours following initiation of cisplatin chemotherapy)</time_frame>
    <description>The number of patients who reported No Vomiting in the 120 hours following initiation of cisplatin chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2322</enrollment>
  <condition>Chemotherapy-Induced Nausea and Vomiting (CINV)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: study medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: Active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: fosaprepitant dimeglumine</intervention_name>
    <description>single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Aprepitant</intervention_name>
    <description>Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>single IV dose of 32 mg of ondansetron on Day 1.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or female and is at least 18 years of age; scheduled to receive his or
             her first course of cisplatin chemotherapy at a dose of 70 mg/m2 or higher; predicted
             life expectancy of 3 months or greater

          -  Patient is post menopausal or, if premenopausal, must use double-barrier contraception

        Exclusion Criteria:

          -  Patient has symptomatic primary or metastatic CNS malignancy

          -  Patient has received or will receive Radiation therapy to the abdomen or pelvis in the
             week prior to Treatment Day 1 though Day 6

          -  Patient has vomited in the 24 hours prior to treatment Day 1

          -  Patient has an active infection; Patient uses illicit drugs or has current evidence of
             alcohol abuse

          -  Patient is pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
    <country>Venezuela</country>
  </removed_countries>
  <results_reference>
    <citation>Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011 Apr 10;29(11):1495-501. doi: 10.1200/JCO.2010.31.7859. Epub 2011 Mar 7.</citation>
    <PMID>21383291</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <results_first_submitted>January 19, 2010</results_first_submitted>
  <results_first_submitted_qc>January 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2010</results_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 149 medical centers worldwide. The recruitment period was from 12 Feb 08 through 8 Jun 09.</recruitment_details>
      <pre_assignment_details>Cisplatin-naïve patients scheduled to receive cisplatin chemotherapy at a dose of 70 mg/m2 or higher for a documented solid malignancy were screened up to 30 days prior to initiation of chemotherapy. Screening included a complete medical history and physical exam. Informed consent was obtained for patients who agreed to participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fosaprepitant</title>
          <description>Fosaprepitant dimeglumine 150 mg IV, ondansetron 32 mg IV, and dexamethasone 12 mg by mouth (PO) on Day 1, dexamethasone 8 mg PO on Day 2, and dexamethasone 16 mg PO on Days 3 and 4.</description>
        </group>
        <group group_id="P2">
          <title>Aprepitant</title>
          <description>Aprepitant 125 mg by mouth (PO), ondansetron 32 mg IV, and dexamethasone 12 mg PO on Day 1, aprepitant 80 mg PO and dexamethasone 8 mg PO on Days 2 and 3, dexamethasone 8 mg PO on Day 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1147"/>
                <participants group_id="P2" count="1175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1080"/>
                <participants group_id="P2" count="1094"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fosaprepitant</title>
          <description>Fosaprepitant dimeglumine 150 mg IV, ondansetron 32 mg IV, and dexamethasone 12 mg by mouth (PO) on Day 1, dexamethasone 8 mg PO on Day 2, and dexamethasone 16 mg PO on Days 3 and 4.</description>
        </group>
        <group group_id="B2">
          <title>Aprepitant</title>
          <description>Aprepitant 125 mg by mouth (PO), ondansetron 32 mg IV, and dexamethasone 12 mg PO on Day 1, aprepitant 80 mg PO and dexamethasone 8 mg PO on Days 2 and 3, dexamethasone 8 mg PO on Day 4.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1147"/>
            <count group_id="B2" value="1175"/>
            <count group_id="B3" value="2322"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" lower_limit="19" upper_limit="86"/>
                    <measurement group_id="B2" value="55.9" lower_limit="19" upper_limit="82"/>
                    <measurement group_id="B3" value="55.6" lower_limit="19" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="425"/>
                    <measurement group_id="B2" value="427"/>
                    <measurement group_id="B3" value="852"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="722"/>
                    <measurement group_id="B2" value="748"/>
                    <measurement group_id="B3" value="1470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="296"/>
                    <measurement group_id="B2" value="306"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="648"/>
                    <measurement group_id="B2" value="655"/>
                    <measurement group_id="B3" value="1303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Motion Sickness</title>
          <description>Includes treated patients only.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1143"/>
                    <measurement group_id="B2" value="1166"/>
                    <measurement group_id="B3" value="2309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Data - Assessment Not Completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Vomiting with Pregnancy</title>
          <description>Measure is specific to female treated patients only.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="420"/>
                    <measurement group_id="B2" value="421"/>
                    <measurement group_id="B3" value="841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female Patients with No Data - No Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Applicable - Male Patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="722"/>
                    <measurement group_id="B2" value="748"/>
                    <measurement group_id="B3" value="1470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).</title>
        <description>The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 120 hours following initiation of cisplatin chemotherapy.</description>
        <time_frame>Overall (in the 120 hours following initiation of cisplatin chemotherapy).</time_frame>
        <population>FAS (Full Analysis Set) patient population was used for all efficacy evaluations and included patients who: 1) received at least one dose of study therapy, 2) received cisplatin chemotherapy, and 3) had at least one post-treatment efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Fosaprepitant</title>
            <description>Fosaprepitant dimeglumine 150 mg IV, ondansetron 32 mg IV, and dexamethasone 12 mg by mouth (PO) on Day 1, dexamethasone 8 mg PO on Day 2, and dexamethasone 16 mg PO on Days 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Aprepitant</title>
            <description>Aprepitant 125 mg by mouth (PO), ondansetron 32 mg IV, and dexamethasone 12 mg PO on Day 1, aprepitant 80 mg PO and dexamethasone 8 mg PO on Days 2 and 3, dexamethasone 8 mg PO on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).</title>
          <description>The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 120 hours following initiation of cisplatin chemotherapy.</description>
          <population>FAS (Full Analysis Set) patient population was used for all efficacy evaluations and included patients who: 1) received at least one dose of study therapy, 2) received cisplatin chemotherapy, and 3) had at least one post-treatment efficacy assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1106"/>
                <count group_id="O2" value="1134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="795"/>
                    <measurement group_id="O2" value="820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the CI for the difference in response rates (Fosaprepitant minus Aprepitant), calculated using the methodology of Miettinen and Nurminen, had a lower limit ≥7 percentage points, fosaprepitant was considered at least as effective as aprepitant for Complete Response in the overall phase. Study had 90% power to detect non-inferiority for this outcome measure.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).</title>
        <description>The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 25 to 120 hours following initiation of cisplatin chemotherapy.</description>
        <time_frame>Delayed phase (25 to 120 hours following initiation of cisplatin).</time_frame>
        <population>FAS (Full Analysis Set) patient population was used for all efficacy evaluations and included patients who: 1) received at least one dose of study therapy, 2) received cisplatin chemotherapy, and 3) had at least one post-treatment efficacy assessment. 1 patient (aprepitant group) had no delayed phase data, and was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fosaprepitant</title>
            <description>Fosaprepitant dimeglumine 150 mg IV, ondansetron 32 mg IV, and dexamethasone 12 mg by mouth (PO) on Day 1, dexamethasone 8 mg PO on Day 2, and dexamethasone 16 mg PO on Days 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Aprepitant</title>
            <description>Aprepitant 125 mg by mouth (PO), ondansetron 32 mg IV, and dexamethasone 12 mg PO on Day 1, aprepitant 80 mg PO and dexamethasone 8 mg PO on Days 2 and 3, dexamethasone 8 mg PO on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).</title>
          <description>The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 25 to 120 hours following initiation of cisplatin chemotherapy.</description>
          <population>FAS (Full Analysis Set) patient population was used for all efficacy evaluations and included patients who: 1) received at least one dose of study therapy, 2) received cisplatin chemotherapy, and 3) had at least one post-treatment efficacy assessment. 1 patient (aprepitant group) had no delayed phase data, and was not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1106"/>
                <count group_id="O2" value="1133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="822"/>
                    <measurement group_id="O2" value="841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the CI for the difference in response rates, calculated using the methodology of Miettinen and Nurminen, had a lower limit ≥7.3 percentage points, fosaprepitant was considered at least as effective as aprepitant for Complete Response in the delayed phase.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>No Vomiting Overall (in the 120 Hours Following Initiation of Cisplatin)</title>
        <description>The number of patients who reported No Vomiting in the 120 hours following initiation of cisplatin chemotherapy.</description>
        <time_frame>Overall (the 120 hours following initiation of cisplatin chemotherapy)</time_frame>
        <population>FAS (Full Analysis Set) patient population was used for all efficacy evaluations and included patients who: 1) received at least one dose of study therapy, 2) received cisplatin chemotherapy, and 3) had at least one post-treatment efficacy assessment. 2 patients (aprepitant group) had no vomiting data, and were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fosaprepitant</title>
            <description>Fosaprepitant dimeglumine 150 mg IV, ondansetron 32 mg IV, and dexamethasone 12 mg by mouth (PO) on Day 1, dexamethasone 8 mg PO on Day 2, and dexamethasone 16 mg PO on Days 3 and 4.</description>
          </group>
          <group group_id="O2">
            <title>Aprepitant</title>
            <description>Aprepitant 125 mg by mouth (PO), ondansetron 32 mg IV, and dexamethasone 12 mg PO on Day 1, aprepitant 80 mg PO and dexamethasone 8 mg PO on Days 2 and 3, dexamethasone 8 mg PO on Day 4.</description>
          </group>
        </group_list>
        <measure>
          <title>No Vomiting Overall (in the 120 Hours Following Initiation of Cisplatin)</title>
          <description>The number of patients who reported No Vomiting in the 120 hours following initiation of cisplatin chemotherapy.</description>
          <population>FAS (Full Analysis Set) patient population was used for all efficacy evaluations and included patients who: 1) received at least one dose of study therapy, 2) received cisplatin chemotherapy, and 3) had at least one post-treatment efficacy assessment. 2 patients (aprepitant group) had no vomiting data, and were excluded from this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1106"/>
                <count group_id="O2" value="1132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="806"/>
                    <measurement group_id="O2" value="844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the CI for the difference in response rates, calculated using the methodology of Miettinen and Nurminen, had a lower limit ≥8.2 percentage points, fosaprepitant was considered at least as effective as aprepitant for No Vomiting in the overall phase.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected starting from the Pre-Study Visit (Day -30 to Day -1) up to 14 days after the patient’s last dose of study drug.</time_frame>
      <desc>Severe infusion site pain, severe infusion site erythema and/or severe infusion site induration, as well as any episode of infusion site thrombophlebitis were designated Events of Clinical Interest (ECI) and evaluated using a predefined severity assessment scale.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fosaprepitant</title>
          <description>Fosaprepitant dimeglumine 150 mg IV, ondansetron 32 mg IV, and dexamethasone 12 mg by mouth (PO) on Day 1, dexamethasone 8 mg PO on Day 2, and dexamethasone 16 mg PO on Days 3 and 4.
4 patients from the fosaprepitant regimen were randomized to the study, but discontinued before receiving study drug. These patients were excluded from the Adverse Event tables.</description>
        </group>
        <group group_id="E2">
          <title>Aprepitant</title>
          <description>Aprepitant 125 mg by mouth (PO), ondansetron 32 mg IV, and dexamethasone 12 mg PO on Day 1, aprepitant 80 mg PO and dexamethasone 8 mg PO on Days 2 and 3, dexamethasone 8 mg PO on Day 4.
6 patients from the aprepitant regimen were randomized to the study, but discontinued before receiving study drug. These patients were excluded from the Adverse Event tables.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Incision site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA Version 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="636" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="679" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1169"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1143"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

